Table 1—

Baseline characteristics of patients (all treatment groups pooled)

CharacteristicsStudy 1Study 2
Sample size n895681
Age yrs#38 (15–85)33 (15–79)
Sex
Male n (%)354 (40)305 (45)
Female n (%)541 (60)376 (55)
FEV1 L2.2±0.62.5±0.7
FEV1 % predicted65.2±10.466.8±10.8
Measured-at-clinic PEF L·min−1352.9±123.2388.1±117.4
Patient-reported PEFAM L·min−1334.9±97.4385.3±88.8
Daytime symptom score (0–6)2.4±0.92.5±0.8
“As-needed” β-agonist use puffs·day−15.5±3.85.4±3.2
  • Data are presented as mean±sd, unless otherwise stated

  • FEV1: forced expiratory volume in one second

  • PEFam: morning peak expiratory flow

  • #: expressed as mean (range)

  • Data are from references 13 and 14